Chipscreen Biosciences
微芯生物
Executive Summary
Chipscreen Biosciences is a Shenzhen-based biotech company listed on Shanghai's STAR Market (688321.SS) with clear BIOSECURE status, making it a viable partner for US pharma BD teams. The company recently received clinical trial approvals for sitagliptin sodium metformin extended-release tablets and CS08399 tablets in March 2026, indicating active pipeline progression. With 2024 revenue of ¥481M but negative net profit of ¥51M, the company appears to be in a typical biotech cash-burn phase while advancing clinical programs. Recent share buyback activities suggest management confidence and potential preparation for strategic partnerships.
Structure: Chipscreen Biosciences operates as a domestic Chinese biotech company listed directly on the Shanghai STAR Market without apparent VIE structure complexities. The company recently changed its sponsor representatives, indicating potential restructuring or preparation for new business initiatives. No subsidiary information is available, suggesting either a simplified structure or limited public disclosure.
Latest Financials
Revenue: 481115043.66, Net Profit: -51084939.83. Source: East Money (688321)
Period: 2024-09-30 | Source: eastmoney
Corporate Events
微芯生物：自愿披露关于西格列他钠二甲双胍缓释片获得药物临床试验批准通知书的公告
CNINFO announcement for Chipscreen Biosciences (688321.SS)
微芯生物：自愿披露关于CS08399片获得药物临床试验批准通知书的公告
CNINFO announcement for Chipscreen Biosciences (688321.SS)
微芯生物：关于更换持续督导保荐代表人的公告
CNINFO announcement for Chipscreen Biosciences (688321.SS)
微芯生物：关于以集中竞价交易方式首次回购公司股份的公告
CNINFO announcement for Chipscreen Biosciences (688321.SS)
微芯生物：关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
CNINFO announcement for Chipscreen Biosciences (688321.SS)
Chipscreen Biosciences Financial Report
Revenue: 481115043.66, Net Profit: -51084939.83. Source: East Money (688321)
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC Category restrictions
Key Exposures:
- •Standard China-based biotech regulatory compliance requirements
Mitigation: No specific mitigation required given clear BIOSECURE status
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific recent out-licensing deals identified, but recent clinical approvals suggest pipeline assets ready for partnership discussions
Approach: Approach with focus on metabolic disease assets, particularly the sitagliptin combination therapy. Company's recent clinical approvals and share buyback suggest active business development phase.
Red Flags
- ⚠Negative profitability with ¥51M loss in 2024
- ⚠Limited public disclosure on key management and corporate structure
- ⚠No identified international partnerships or global development experience
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.